Passage Bio Statistics
Total Valuation
Passage Bio has a market cap or net worth of $17.71 million. The enterprise value is -$9.81 million.
Important Dates
The next estimated earnings date is Tuesday, May 26, 2026, before market open.
| Earnings Date | May 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Passage Bio has 3.21 million shares outstanding. The number of shares has increased by 3.06% in one year.
| Current Share Class | 3.21M |
| Shares Outstanding | 3.21M |
| Shares Change (YoY) | +3.06% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 42.63% |
| Float | 2.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.37 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.49.
| Current Ratio | 1.73 |
| Quick Ratio | 1.66 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -128.90% and return on invested capital (ROIC) is -52.58%.
| Return on Equity (ROE) | -128.90% |
| Return on Assets (ROA) | -38.35% |
| Return on Invested Capital (ROIC) | -52.58% |
| Return on Capital Employed (ROCE) | -229.71% |
| Weighted Average Cost of Capital (WACC) | 8.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.57M |
| Employee Count | 24 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.48% in the last 52 weeks. The beta is 1.38, so Passage Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | -10.48% |
| 50-Day Moving Average | 7.30 |
| 200-Day Moving Average | 8.55 |
| Relative Strength Index (RSI) | 44.59 |
| Average Volume (20 Days) | 158,858 |
Short Selling Information
The latest short interest is 68,090, so 2.12% of the outstanding shares have been sold short.
| Short Interest | 68,090 |
| Short Previous Month | 114,499 |
| Short % of Shares Out | 2.12% |
| Short % of Float | 2.36% |
| Short Ratio (days to cover) | 1.63 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -37.58M |
| Pretax Income | -37.68M |
| Net Income | -37.68M |
| EBITDA | -36.92M |
| EBIT | -37.58M |
| Earnings Per Share (EPS) | -$11.84 |
Full Income Statement Balance Sheet
The company has $33.34 million in cash and $5.76 million in debt, with a net cash position of $27.58 million or $8.60 per share.
| Cash & Cash Equivalents | 33.34M |
| Total Debt | 5.76M |
| Net Cash | 27.58M |
| Net Cash Per Share | $8.60 |
| Equity (Book Value) | 11.75M |
| Book Value Per Share | 3.66 |
| Working Capital | 14.64M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -30.65M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 728,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -31.51M |
| FCF Per Share | -$9.82 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Passage Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.06% |
| Shareholder Yield | -3.06% |
| Earnings Yield | -212.01% |
| FCF Yield | -177.30% |
Analyst Forecast
The average price target for Passage Bio is $14.00, which is 153.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.00 |
| Price Target Difference | 153.62% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |